Cell | Spatial Proximity between LAG-3 and TCR Guides T Cell Suppression and Mechanisms of Autoimmunity Regulation

This study reveals the conditional activation mechanism of LAG-3 inhibitory function, providing key strategic guidance for the precision drug design of autoimmune diseases and experimental regulation of T cell function.

 

Literature Overview

This article, titled "Proximity between LAG-3 and the T Cell Receptor Guides Suppression of T Cell Activation and Autoimmunity," published in the journal Cell, systematically explores the spatial mechanism of the immune checkpoint receptor LAG-3 in suppressing T cell activation and its translational potential in treating autoimmune diseases. The study indicates that traditional MHC-II binding alone is insufficient to fully explain LAG-3's inhibitory function; its core lies in the spatial proximity between LAG-3 and the T cell receptor (TCR). This proximity is mediated by specific peptide-MHC-II complexes, which subsequently block signal transduction by disrupting the phase-separated condensates of CD3ε and Lck.

Background Knowledge

The pathogenesis of autoimmune diseases such as Type 1 Diabetes, Multiple Sclerosis, and Autoimmune Hepatitis involves the overactivation of T cells. Current therapeutic approaches targeting T cells often lack specificity, potentially leading to immunodeficiency or increased infection risks. LAG-3, an inhibitory receptor highly expressed on activated T cells, has long been considered a therapeutic target, yet its mechanism of action remains controversial. Previous studies suggested LAG-3 functions by binding to MHC-II or FGL1, but clinical data indicate limited efficacy as a monotherapy. This study focuses on elucidating the "spatial licensing" mechanism required for LAG-3 to exert inhibition, specifically the necessity of forming cis-proximity with the TCR at the immunological synapse. This finding explains why non-specific blocking of MHC-II fails to effectively mimic LAG-3's inhibitory effects and provides a theoretical basis for developing novel bispecific antibodies.

 

 

Research Methods and Core Experiments

The authors constructed various artificial antigen-presenting cell (aAPC) models expressing either specific pMHC-II or non-specific pMHC, combined with a LAG-3 chimeric antigen receptor (CAR) reporter system, to precisely resolve the conditions for LAG-3 signal activation. Using a chemically induced proximity system (Rapalog), the research team artificially brought LAG-3 and TCR into close proximity, confirming that spatial proximity is critical for LAG-3's inhibitory function. At the molecular level, utilizing in vitro phase separation assays and surface plasmon resonance technology, the study found that the FSAL motif in the LAG-3 intracellular domain forms condensates with CD3ε, specifically disrupting the interaction between CD3ε and Lck. Furthermore, the team designed LAG-3/TCR bispecific silencing antibodies (BiTS) and validated their therapeutic efficacy in multiple mouse models, including Type 1 Diabetes (RIP-OVA model), T cell hepatitis, and Experimental Autoimmune Encephalomyelitis (EAE).

Key Conclusions and Perspectives

• LAG-3's inhibitory function depends on its spatial proximity to the TCR rather than simple MHC-II binding; specific pMHC-II bridges LAG-3 and TCR, triggering inhibitory signals.
• The FSAL motif in the LAG-3 intracellular domain mediates phase-separated condensation with CD3ε, blocking the early signal cascade of T cell activation by physically isolating CD3ε from Lck.
• LAG-3/TCR bispecific antibodies (BiTS), designed based on the spatial proximity mechanism, can efficiently inhibit the activation of both CD4+ and CD8+ T cells without relying on CD4 or CD8 co-receptors, significantly reducing pathological damage in various autoimmune disease models.
• This mechanism reveals the unique biological characteristics of LAG-3 as a "conditional" checkpoint, providing precise targets for developing novel immunotherapies for T cell-mediated diseases.

Research Significance and Prospects

This discovery has profound implications for drug development, suggesting that future immune checkpoint agonist designs should focus on mimicking natural spatial proximity effects rather than merely enhancing ligand binding. In terms of clinical monitoring, the co-localization of LAG-3 and TCR may serve as a novel biomarker for assessing T cell inhibitory status. For disease modeling, the BiTS tools and mechanistic models provided by this study will facilitate the construction of more precise autoimmune disease screening platforms, accelerating translational medical research for refractory diseases such as Type 1 Diabetes and Multiple Sclerosis.

 

 

Conclusion

This study provides an in-depth analysis of the molecular mechanism by which LAG-3 suppresses T cell activation, establishing the central role of spatial proximity in immune checkpoint regulation. This finding not only corrects previous understandings of LAG-3's mode of action but also opens a new pathway for the treatment of autoimmune diseases. By developing bispecific antibodies capable of forcibly reducing the distance between LAG-3 and TCR, the research team successfully achieved precise inhibition of pathogenic T cells while avoiding the side effects associated with broad-spectrum immunosuppression. From the exploration of basic mechanisms in the laboratory to the significant validation of efficacy in preclinical mouse models, this achievement demonstrates a complete chain from molecular mechanism understanding to clinical translational application. For related diseases lacking effective treatment options, such as Type 1 Diabetes, Autoimmune Hepatitis, and Multiple Sclerosis, this spatial proximity-based regulatory strategy is expected to become a cornerstone of future immunotherapy systems, offering patients safer and more effective treatment hopes.

 

Jasper Du, Hui Chen, Jia You, Jizhong Lou, and Jun Wang. Proximity between LAG-3 and the T Cell Receptor Guides Suppression of T Cell Activation and Autoimmunity. Cell.